EDAP TMS S.A. Launches Ablatherm-HIFU at the National Cancer Institute, Aviano, Italy
May 08 2006 - 1:15PM
PR Newswire (US)
Center Concludes Ablatherm-HIFU to Be Attractive Choice in First
Indication, Salvage Treatments LYON, France, May 8
/PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ:EDAP) announced the
launch of Ablatherm-HIFU treatment for localized prostate cancer at
the National Cancer Institute, Centro Referimento Oncologico (CRO),
in cooperation with Pordenone Hospital in Aviano, Italy. CRO is one
of the largest oncology centers in Italy and represents a
cooperative approach between radiotherapists, oncologists and
urologists in the treatment of prostate cancer. The center will be
using the Ablatherm-HIFU unit on EDAP's revenue per procedure (RPP)
model. Ablatherm-HIFU technology was selected after an extensive
review of clinical data demonstrating its best-in-class technology
and consistent clinical follow-up. During a symposium event at the
recent 2006 European Association of Urology Congress in Paris,
Professor U. Tirelli of CRO described the reasons for electing to
pursue Ablatherm-HIFU as a therapeutic offering. Pr. Tirelli's
presentation indicated Ablatherm-HIFU represents a future
noninvasive gold-standard in treating non-surgical patients with
localized prostate cancer and is possibly today the best solution
for salvage treatment of patients suffering a recurrence following
radiation failure. The center's evaluations also concluded that
Ablatherm-HIFU represented a very safe therapeutic approach without
the common side effects observed after surgery and radiation.
Professor Tirelli stated, "Medical oncologists are often seen as
arbitrators between surgical and radiotherapy options for patients
with localized prostate cancer. Ablatherm-HIFU is a very attractive
approach in many cases due to solid results and low side effects as
clearly demonstrated in the medical studies done to date. At our
cancer institution, both surgeons and radiotherapists are
concordant for the introduction of HIFU in the management of our
patients with localized, locally advanced and locally recurrent
prostate cancer. With more than half of patients diagnosed over the
age of 70, which frequently excludes them from surgical options,
and additional patients wishing to avoid surgery or radiation,
Ablatherm-HIFU represents an important therapeutic tool.
Ablatherm-HIFU also now offers a new gold standard in the treatment
of patients who failed radiation therapy as it offers a curative
approach with strong efficacy and low side effects compared to
current therapies. We believe urologists and their patients will be
attracted to our center in performing treatment due to this new and
uniquely beneficial offering." "We are pleased to begin offering
service at such an important center," said Sergio Pontecorvi,
General Manager of EDAP Technomed Italy. "CRO has done an extensive
evaluation of HIFU technology and concluded the Ablatherm- HIFU is
the strongest device in the treatment of localized prostate cancer
due to its extensive clinical experience now stretching over 10
years. We are pleased to learn of their desire to offer
Ablatherm-HIFU as a new gold standard in not only non-invasive
treatment of localized prostate cancer, but also in the treatment
of locally recurrent prostate cancer. By offering Ablatherm-HIFU
therapy in their treatment mix, the center at Aviano will be able
to attract a larger number of patients seeking its uniquely minimal
impact on their quality of life. We believe this desire coupled
with the readily accessible revenue per procedure model will allow
us to reach a broader number of patients in the future." About EDAP
TMS S.A. EDAP TMS S.A. develops and markets Ablatherm, the most
advanced and clinically proven choice for High Intensity Focused
Ultrasound (HIFU) treatment of localized prostate cancer. HIFU
treatment is shown to be a minimally invasive and effective
treatment option with a low occurrence of side effects.
Ablatherm-HIFU is generally recommended for patients with localized
prostate cancer (stages T1-T2) who are not candidates for surgery
or who prefer an alternative option or patients who failed
radiotherapy treatment. The company is also developing this
technology for the treatment of certain other types of tumors. EDAP
TMS S.A. also produces and commercializes medical equipment for
treatment of urinary tract stones using Extra-corporeal Shockwave
Lithotripsy (ESWL). For more information on the Company, contact
Halliburton Investor Relations at (972) 458-8000, the Corporate
Investor Relations Dept at +33 (0) 4 78 26 40 46 or see the
Company's Web sites at http://www.edap-tms.com/ and
http://www.hifu-planet.com/ . This press release contains, in
addition to historical information, forward-looking statements that
involve risks and uncertainties. These include statements regarding
the Company's growth and expansion plans. Such statements are based
on management's current expectations and are subject to a number of
uncertainties and risks that could cause actual results to differ
materially from those described in the forward-looking statements.
Factors that may cause such a difference include, but are not
limited to, those described in the Company's filings with the
Securities and Exchange Commission. Ablatherm-HIFU treatment is in
clinical trials but not yet FDA approved or marketed in the United
States. CONTACT: EDAP TMS S.A. Hugues de Bantel - Philippe Chauveau
Blandine Confort +33 4 78 26 40 46 Halliburton Investor Relations
Matt Kreps - Geralyn DeBusk 972 458 8000 DATASOURCE: EDAP TMS S.A.
CONTACT: Hugues de Bantel, Philippe Chauveau, or Blandine Confort,
all of EDAP TMS S.A., +33-4-78-26-40-46; or Matt Kreps or Geralyn
DeBusk, both of Halliburton Investor Relations, +1-972-458-8000,
for EDAP TMS S.A. Web site: http://www.edap-tms.com/
http://www.hifu-planet.com/
Copyright
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024